|
| ||
|
|
||
Biotech Industry (biotech + industry)
Selected AbstractsEarnings and Equity Valuation in the Biotech Industry: Theory and EvidenceFINANCIAL MANAGEMENT, Issue 3 2008Philip Joos We examine how the price-earnings relation varies with the uncertainty about and the quality of a firm's investments. We develop a real option valuation framework to capture investment and abandonment options in the research-intensive biotechnology industry. We hypothesize that the price-earnings relation will be V-shaped and change over the firm's life cycle. We also show how nonfinancial information affects the pricing of earnings. Our empirical findings are based on a sample of 301 biotechnology firms that made IPOs between 1980 and 2000, and are generally consistent with our predictions. [source] The Impact of Regulations on Firms: A Case Study of the Biotech Industry,LAW & POLICY, Issue 3 2005FILIPPA CORNELIUSSEN Drawing on semi-structured interviews carried out with founders, managers, and senior scientists in start-up biotech firms, this paper illustrates that the socio-legal literature's characterization of small firms as less compliance oriented is too neat. Small firms do not necessarily have a limited knowledge and comprehension of the law. Nor do they necessarily have low levels of motivation to improve and maintain health and safety standards. In fact, the opposite may be true. Small firms may approach the regulatory ideal where the routines, procedures, and precautionary measures prescribed by regulations permeate the organizations. [source] An approach for post-market monitoring of potential environmental effects of Bt -maize expressing Cry1Ab on natural enemiesJOURNAL OF APPLIED ENTOMOLOGY, Issue 4 2009O. Sanvido Abstract Post-market monitoring (PMM) consistent with Swiss and European Union legislation should ensure the detection and prevention of adverse effects on the environment possibly deriving from commercial cultivation of genetically modified (GM) crops. Insect-resistant GM crops (such as Bt -maize) raise particular questions regarding disturbances of biological control functions provided by beneficial insects such as predators and parasitoids (so-called natural enemies). Consensus among regulators, scientists and the agricultural biotech industry on appropriate PMM plans allowing the detection and possibly prevention of such adverse effects is still lacking. The aims of this study were to identify the necessity for PMM of Bt -maize expressing Cry1Ab on natural enemies and to develop an appropriate PMM plan. The approach chosen consisted in determining what type of monitoring is most appropriate to address potential effects of Bt -maize on natural enemies during commercial cultivation. This included identifying whether there remain substantial scientific uncertainties that would support case-specific monitoring. Existing pre-market risk assessment data indicate that Bt -maize (Cry1Ab) comprises a negligible risk for disturbances in biological control functions of natural enemies. As a consequence, a faunistic monitoring of specific groups of natural enemies is not considered an appropriate approach to detect failures in biological control functions. Alternatively, an approach is proposed that consists in indirectly analysing biological control functions by surveying outbreaks of maize herbivores. Unusual herbivore outbreaks could indicate failures in biological control functions of natural enemies. Data could be collected via questionnaires addressed to farmers growing Bt -maize. Significant correlations between unusual occurrences of specific maize herbivores and the cultivation of Bt -maize would subsequently need specific studies to determine possible causalities in more detail. The here proposed approach has the advantage of covering different natural enemy groups. It represents a cost-effective strategy to obtain scientifically sound data as a basis for regulatory decision-making. [source] Biotech round the world: Focus on CanadaBIOTECHNOLOGY JOURNAL, Issue 7 2008Article first published online: 15 JUL 200 Canada's biotech industry Competitive strengths and capabilities Key Canadian biotech clusters Canada as an investment destination [source] | ||||||||||